menu
    • menu
    [{"orgOrder":0,"company":"RadioMedix","sponsor":"Oranomed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Alphamedix","moa":"Somatostatin receptor (SSTR)","graph1":"Oncology","graph2":"Phase II","graph3":"RadioMedix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RadioMedix \/ Oranomed","highestDevelopmentStatusID":"8","companyTruncated":"RadioMedix \/ Oranomed"},{"orgOrder":0,"company":"RadioMedix","sponsor":"Oranomed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Alphamedix","moa":"Somatostatin receptor (SSTR)","graph1":"Oncology","graph2":"Phase II","graph3":"RadioMedix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RadioMedix \/ Oranomed","highestDevelopmentStatusID":"8","companyTruncated":"RadioMedix \/ Oranomed"}]

    Find Clinical Drug Pipeline Developments & Deals for Alphamedix

    Menu

    Alphamedix

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            RadioMedix

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            RadioMedix

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alphamedix

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Oranomed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients

                            Details : Alphamedix is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neuroendocrine Tumors.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            December 10, 2021

                            Lead Product(s) : Alphamedix

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Oranomed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            RadioMedix

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            RadioMedix

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alphamedix

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Oranomed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1 Study of AlphaMedixâ„¢ in Adult Subjects With SSTR (+) NET

                            Details : Alphamedix is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neuroendocrine Tumors.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            March 15, 2018

                            Lead Product(s) : Alphamedix

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Oranomed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth